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InMycobacterium, multidrug efflux pumps can be associated with intrinsic drug resistance. Comparison of putative mycobacte-
rial transport genes revealed a single annotated open reading frame (ORF) for a multidrug and toxic compound extrusion
(MATE) family efflux pump in all sequenced mycobacteria exceptMycobacterium leprae. Since MATE efflux pumps function as
multidrug efflux pumps by conferring resistance to structurally diverse antibiotics and DNA-damaging chemicals, we studied
this gene (MSMEG_2631) inM. smegmatismc2155 and determined that it encodes a MATE efflux system that contributes to in-
trinsic resistance ofMycobacterium. We propose that the MSMEG_2631 gene be namedmmp, for mycobacterial MATE protein.
Biolog PhenotypeMicroArray data indicated thatmmp deletion increased susceptibility for phleomycin, bleomycin, capreomy-
cin, amikacin, kanamycin, cetylpyridinium chloride, and several sulfa drugs. MSMEG_2619 (efpA) andMSMEG_3563mask the
effect ofmmp deletion due to overlapping efflux capabilities. We present evidence thatmmp is a part of anMSMEG_2626-2628-
2629-2630-2631 operon regulated by a strong constitutive promoter, initiated from a single transcription start site. All together,
our results show thatM. smegmatis constitutively encodes an Na-dependent MATEmultidrug efflux pump frommmp in an
operon with putative genes encoding proteins for apparently unrelated functions.
Tuberculosis (TB) is still one of the biggest killers; it is estimatedthat Mycobacterium tuberculosis causes 8.8 million new cases
of TB and kills 1.4 million people per year (1). Factors contribut-
ing to therapeutic complications are latency in an asymptomatic
host and later reactivation to cause active disease (2, 3), intrinsic
antibiotic resistance (4), and acquired drug resistance (5). Multi-
drug-resistant (MDR) strains further complicate therapy. Al-
though changes responsible for acquired resistance are often un-
derstood (6–10), the basis of MDR is not yet fully defined (11, 12).
Bacteria have several antibiotic resistance strategies: (i) pro-
duce enzymes to inactivate antibiotics, (ii) alter targets to reduce
antibiotic affinity, and (iii) reduce drug accumulation by de-
creased permeability or increased efflux (4). These strategies may
be an intrinsic feature of an organism or acquired via mutations or
acquisition of exogenous genes (13, 14). Low mycobacterial cell
wall permeability due to its lipid-rich composition, limiting drug
entry, is one reason for intrinsic resistance (15, 16), but Mycobac-
terium also has several multidrug efflux pumps (17) that enhance
drug resistance by drug extrusion; however, their roles in intrinsic
resistance are not well explored.
Multidrug efflux pumps extrude a wide range of structurally
unrelated compounds and belong to five families: (i) ATP binding
cassette (ABC), (ii) major facilitator superfamily (MFS), (iii) small
multidrug resistance (SMR), (iv) resistance-nodulation-division
(RND), and (v) multidrug and toxic compound extrusion
(MATE). ABC family members are ATP-dependent primary
transporters, but the other families are secondary transporters
that use an electrochemical transmembrane gradient. MATE pro-
teins (18) have a 12-membrane helix topology and use either H
or Na gradients to drive efflux (19). In plants, MATE transport-
ers secrete secondary metabolites to defend against microbial
pathogens (20, 21), and in the liver and kidney they extrude xeno-
biotic cations (22, 23). Bacterial MATE transporters function as
xenobiotic efflux pumps and can confer resistance to structurally
diverse drugs, including antibiotics and DNA-damaging agents
(24, 25).
MATE systems from only a few eukaryotes (26) and pro-
karyotes (19) have been functionally characterized. The role for
most reported prokaryotic MATE transporters is not well defined,
since most have been studied by heterologous expression (19). To
investigate the role of a MATE transporter in Mycobacterium in-
trinsic resistance, we made an M. smegmatis mutant lacking this
protein and characterized it using Phenotype MicroArray (PM).
The present study reveals the polyspecific and Na-dependent
nature of the M. smegmatis MATE transporter and transcriptional
coupling of its gene with 4 upstream genes. By determining the
transcription start site, we have also identified its promoter and
examined its activity.
MATERIALS AND METHODS
Bacterial strains, growth conditions, plasmids, and chemicals. Table 1
describes the strains and plasmids used. Mycobacteria were cultivated at
37°C in Difco 7H9 broth supplemented with 0.2% (vol/vol) glycerol and
0.05% (wt/vol) Tween 80 or on Difco 7H10 agar plates supplemented with
0.2% (vol/vol) glycerol. Escherichia coli was grown at 37°C (or 30°C when
using strain BW25113/pKD46) in Luria-Bertani broth. Plasmids were
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maintained in E. coli DH5 with 100 g ampicillin (Amp), 75 g kana-
mycin (Km), or 25 g gentamicin (Gen) per ml.
Bioinformatic analysis. Mycobacterial transporter families were
compared using TransportDB (http://www.membranetransport.org/)
(32). Protein BLAST analysis was performed via the National Center for
Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov
/BLAST). MATE homologs were retrieved from GenBank (http://www.
ncbi.nlm.nih.gov/GenBank/). ClustalW2 (http://www.ebi.ac.uk/Tools
/msa/clustalw2/) and MEGA (33) were used for multiple sequence align-
ment and phylogenetic trees. Chromosomal regions were retrieved from
NCBI (http://www.ncbi.nlm.nih.gov/genome/) and J. Craig Venter Insti-
tute-Comprehensive Microbial Resource (JCVI-CMR; http://cmr.jcvi
.org/tigr-scripts/CMR). Sequence Manipulation Suite (http://www
.ualberta.ca/) (34) and Vector NTI Advance (Invitrogen) were used for
molecular weight estimation, genomic map construction, and primer de-
sign.
Mutant construction.M. smegmatis mutants were constructed using
homologous recombination as follows. The mmp (MSMEG_2631) locus
was PCR amplified using 2629:F:XbaI/2633:R:BglII primers to produce a
4,030-bp fragment, which was cloned in pJQ200 (28) to generate pLD183,
which was transferred to E. coli25113/pKD46 (to use the -Red recombi-
nase system [27]) and grown at 30°C in the presence of 1 mM arabinose to
make electrocompetent cells. The Km resistance gene was PCR amplified
from pKD4 (27) using primers 2631:H1/2631:H2, designed to produce a
40-bp homologous region for mmp at both ends. PCR product was puri-
fied and electroporated into 25113/pKD46 having pLD183. Transfor-
mants were selected with Km (75 g/ml) at 37°C on LB plates. Plasmids
were isolated and examined for Kmr cassette insertion in mmp and desig-
nated pLD187. pLD187 was mobilized in M. smegmatis mc2155, and
transformants were selected with Km (50g mg1) and 2% sucrose on LB
plates. Disruption was confirmed by PCR, and confirmed mutants were
designated LD1158. Unmarked mmp deletion mutants were developed
using the FLP/FLP recognition target (FLP/FRT) system. A variant of
pMN234 (29) that has a Genr cassette (S. Jaques and L. Daniels, unpub-
lished data) in the place of the Kmr cassette in pMN234 was mobilized in
LD1158, and transformants were selected with gentamicin (20 g ml1)
on LB plates. Transformants were kept with gentamicin for 2 to 3 revivals
and transferred to plain LB plates, and Kmr cassette deletion was con-
firmed by Km sensitivity and PCR assays. Mutants with confirmed dele-
tion of MSMEG_2631 (MSMEG2631) were designated LD1184. The
same procedure was used to develop all unmarked deletion mutants.
Construction of complementation plasmids. M. smegmatis (mmp)
and Mycobacterium bovis BCG (BCG_2856c) were PCR amplified using
2631:F:NdeI/2631:R:MluI and dinF:F:NdeI/dinF:R:MluI primers, respec-
tively. Products digested with NdeI/MluI were ligated with digested
pTB21 (intermediate mycobacterial promoter) or pUV15 (strong myco-
bacterial promoter) to make two expression plasmids for each open read-
ing frame (ORF). Recombinant plasmids were purified, confirmed, and
TABLE 1 Bacterial strains and plasmids used in this study
Strain or plasmids Relevant properties Reference or source
E. coli strains
DH5 lacU169 hsdR17 recA1 endA1 gyrA96 thi-1 relA1 Lab collection
BW25113 lacIq rrnBT14 lacZWJ16 hsdR514 araBADAH33 rhaBADLD78 27
M. smegmatis strains
mc2 155 Wild type Lab collection
LD1184 mc2 155 MSMEG_2631 (or mmp) This work
LD1189 mc2 155 MSMEG_2619 This work
LD1192 mc2 155 MSMEG_3563 This work
LD1190 mc2 155 MSMEG_2631-MSMEG_2619 This work
LD1201 mc2 155 MSMEG_2631-MSMEG_3563 This work
Plasmids
pJQ200 Suicide vector containing sacB and Genr gene 28
pKD46 -Red recombinase system, Ampr, temp sensitive 27
pKD4 Plasmid containing FRT-flanked Kmr gene 27
pMN234 Plasmid for expression of flp gene; Kmr 29
pTB21 Pimyc-gfpuv fusion; Hyg
r; Kmr 30
pUV15 Psmyc-gfpuv fusion; Hyg
r; Kmr 30
pTL61T lacZ transcriptional fusion vector with RNaseIII cleavage site; Ampr 31
pLD132 pMN234 derivative; Genr S. Jaques (unpublished data)
pLD150 pTL61T derivative; pAL5000 origin; Genr S. Jaques (unpublished)
pLD182 MSMEG_2619 locus (4,035 bp) cloned in pJQ200 This work
pLD183 MSMEG_2631 locus (4,030 bp) cloned in pJQ200 This work
pLD184 MSMEG_3563 locus (4,475 bp) cloned in pJQ200 This work
pLD186 MSMEG_2619::Kmr in pLD182 This work
pLD187 MSMEG_2631::Kmr in pLD183 This work
pLD190 MSMEG_3563::Kmr in pLD184 This work
pLD216 MSMEG_2631 ORF cloned in NdeI/MluI site of pTB21 This work
pLD217 BCG_2856 (dinF) ORF cloned in NdeI/MluI site of pTB21 This work
pLD221 pTB21 without promoter; digested with XbaI/NheI and self-ligated This work
pLD222 1,011-bp MSMEG_2628 upstream cloned in XbaI/NheI of pTB21 This work
pLD223 1,094-bp MSMEG_2629 upstream cloned in XbaI/NheI of pTB21 This work
pLD224 1,017-bp MSMEG_2630 upstream cloned in XbaI/NheI of pTB21 This work
pLD225 1,019-bp MSMEG_2631 upstream cloned in XbaI/NheI of pTB21 This work
pLD226 375-bp fragment encompassing TSS and promoter cloned in HindIII/XbaI site of pLD150 This work
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electroporated into M. smegmatis. Transformants were selected with 100
g ml1 of hygromycin on LB plates.
PM tests. Phenotype MicroArray (PM; Biolog, Hayward CA) antimi-
crobial susceptibility tests for M. smegmatis were performed with modifi-
cations of earlier methods (35; S. Jaques III and L. Daniels, presented at
the SCASM Conference, Austin, TX, 2008; M. Rahman, S. Jaques III, and
L. Daniels, presented at the SC-ASM Conference, Austin, TX, 2008).
Briefly, cells were streaked onto 7H10 agar plates supplemented with 0.2%
(vol/vol) glycerol and grown 3 to 4 days at 37°C. Growth was removed
from 7H10 plates using a cotton swab dipped in 2% Tween 80, and cells
were suspended in GN/GP-IF-0a (Biolog inoculating fluid) to give 85%
transmittance (Biolog turbidimeter, 20-mm diameter tube). Cell suspen-
sions were diluted 60-fold in 120 ml of 1 IF-10b (Biolog) supplemented
with 1 Biolog Redox Dye Mix H to make inoculum (100 l/well) for 10
plates (PM-11 to -20), which measure sensitivity to antibiotics and other
inhibitors. PM plates were sealed with plastic film (Axygen Inc., Union
City, CA), incubated at 37°C in the OmniLog instrument (Biolog, Hay-
ward, CA) for 168 h, and monitored for color change in the wells. Data
were analyzed with OmniLog-PM software, release OL_PM_109M of 14
January 2002.
MIC determination. MICs were determined in 7H9 medium supple-
mented with Tween 80 and oleic acid-albumin-dextrose-catalase
(OADC) with different inhibitor concentrations. Growth was monitored
visually after 3 to 4 days of growth at 37°C. MIC determination was re-
peated five times, and only results reproduced more than three times are
listed.
EtBr accumulation and efflux assay. Ethidium bromide (EtBr) accu-
mulation and efflux assay was performed as described previously (4, 36).
M. smegmatis was grown at 37°C in 7H9 medium to an optical density at
600 nm (OD600 nm) of ca. 0.7 to 0.8, and cells were harvested, washed twice
with 0.1 M potassium phosphate (pH 7.2), resuspended in the same buffer
at an OD600 nm of 1.2, and shaken for 90 min at 37°C to starve for energy.
EtBr accumulation was monitored in the presence of 50 mM NaCl, 0.2%
glycerol, or NaCl plus glycerol with a NOVOstar microplate reader (BMG
Labtechnologies, Inc., Durham, NC). For efflux assay, cells were loaded
with EtBr by incubating cells in potassium phosphate supplemented with
5M ethidium bromide for 1 h at 37°C. EtBr efflux from loaded cells was
monitored using the same instrument. In both assays, the final EtBr con-
centration was 5 M, and excitation and emission wavelengths were 520
nm and 590 nm, respectively.
RNA extraction and RT-PCR. Total RNA was isolated from 7H9-
grown, mid-exponential-phase M. smegmatis (OD600 nm, ca. 0.8 to 0.9)
using the RNeasy Protect Bacteria Mini Kit (Qiagen). On-column DNase
digestion was performed using RNase-Free DNase (Qiagen). Reverse
transcriptase PCR (RT-PCR) was carried out with 0.3 to 0.5g RNA using
a one-step RT-PCR kit (Qiagen). Cycling conditions were 52°C for 30
min, 95°C for 15 min, 30 cycles of 95°C for 30 s, 56 to 60°C (according to
the primer) for 30 s, and 72°C for 1 min, followed by incubation at 72°C
for 10 min. For two-step RT-PCR, RNA samples were reverse transcribed
using the AffinityScript Multiple Temperature cDNA synthesis kit (Agi-
lent Technologies) with template cDNA with PCR primer sets.
5= RACE. The mmp transcription start site (TSS) was determined us-
ing the 3=/5= rapid amplification of cDNA ends (3=/5=RACE) kit, 2nd
Generation (Roche), according to the manufacturer’s instructions.
Briefly, mmp transcripts were reverse transcribed from total RNA into
cDNA using 2631-SP1:R (Table 2). cDNA was purified using a High Pure
PCR kit (Roche) and 3=-poly(dA) tailed and then used as the template in
two PCRs designed to amplify the 5= end ofmmp and MSMEG_2628 using
oligo(dT)-anchor/2631-SP2:R and oligo(dT)-anchor/2628-SP1:R prim-
ers, respectively. The oligo(dT)-anchor primer was provided in the kit to
anneal to the poly(dA) tail, and 2631-SP2:R (Table 2) was complementary
to a region upstream of the 2631-SP1:R binding site. First PCR products
were separately used as the template in second PCRs using anchor/2631-
SP3:R and anchor/2628-SP2:R primer sets. Anchor primer was provided
in the kit to anneal at a region generated by oligo(dT)-anchor primer at
the 3= end of cDNA, and 2631-SP3:R and 2628-SP2:R (Table 2) were
complementary to the region upstream of 2631-SP2:R and 2628-SP1:R
binding sites, respectively. Product was ligated into pGEM-T Easy (Pro-
mega), and several clones were sequenced.
Promoter:reporter fusion construction and promoter activity de-
termination. A 375-bp fragment (325 to50 of the TSS) was amplified
using Pr:F1:HindIII/Pr:R1:XbaI primers and cloned in pLD150 (a
pTL61T derivative [31] of pAL5000 origin; Genr [Jaques and Daniels,
unpublished]) to construct a promoter:lacZ transcriptional fusion, desig-
nated pLD226. pLD150 and pLD226 were mobilized inM. smegmatis. The
-galactosidase assay (37) was performed with M. smegmatis strains har-
boring pLD150 or pLD226. Cells were grown in 7H9 to mid-exponential
phase and then grown for two more hours after supplementing with EtBr
(2g ml1), norfloxacin (5g/ml), kanamycin (2g ml1), or sulfachlo-
ropyridazine (400 g ml1). Untreated cultures were used as controls.
Assay cell density was equalized by diluting with fresh medium or medium
supplemented with drugs.
Upstream regions of MSMEG_2628, MSMEG_2629, and MSMEG_
2630 and mmp (approximately 1,000 bp) were amplified using primers
2628US:F:XbaI/2628:R:NheI (1,011 bp), 2629US:F:XbaI/2629:R1:NheI
(1,094 bp), 2630US:F:XbaI/2630:R1:NheI (1,017 bp), and 2631US:F:
XbaI/2631:R1:NheI (1,019 bp), respectively. Amplified fragments were
cloned at the XbaI/NheI site of pTB21 to construct promoter:gfpuv trans-
lational fusions by replacing the pTB21 promoter. Constructs with the
upstream region of MSMEG_2628, MSMEG_2629, and MSMEG_2630 and
mmp were designated pLD222, pLD223, pLD224, and pLD225, respec-
tively. XbaI/NheI-digested pTB21 was self-ligated to construct a promot-
erless plasmid, designated pLD221, as a negative control; pTB21 was the
positive control. GFPuv fluorescence was measured with a NOVOstar
TABLE 2 Primers used in this studya
Primer Sequence (5= to 3=)
2629:F:XbaI TGCTCTAGACTGCACGACGCCACGCTGTACTAC
2633:R:BglII GGAAGATCTCAAGTCGACGCTGCTGAAGGTGATC
2631:H1 CGCAGAACCCATCTACCTGCTTTTCGACCTCGCGATC
GTGTAGGCTGGAGCTGCTTC
2631:H2 GCACCATGAACGTGCTGAGCCCCGACCAGATACCGAA
CATATGAATATCCTCCTTAG
2631:F TTGGCTGATGCGGCGGGCGACCTG
2631:R CAAGCGCTGACCTCGTCAGGACGTG
2631:F:NdeI GGAATTCCATATGTTGGCTGATGCGGCGGGCGACCTG
2631:R:MluI TCGACGCGTCAAGCGCTGACCTCGTCAGGACGTG
dinF:F:NdeI GGAATTCCATATGAGCCAGGTGGGGCACCGCGCG
dinF:R:MluI TCGACGCGTCAACACGACGAACAGCGCATAATC
2628:F CAGCCTGGAAGACCTGGATTC
2629:R GTAATCCGGGTCCTCGTCGAG
2629:F GACGCCACGCTGTACTACAC
2630:R CACCTTTTCGTCGATGGGTTTG
2630:F CAAACCCATCGACGAAAAGGTG
2631:R1 GATGATCAGCAGTCCGAGAC
2631-SP1:R CCAGCACGACGTAACGCAAC
2631-SP2:R CAGGATCGCGACACGCAACCAC
2631-SP3:R GATGATCAGCAGTCCGAGACCGAG
2628N-sp2:R CTGCTCTTTGAGCGTTGCTAAG
2628N-SP3:R CTTGCTTGTGACACCGAGTTCCTTTG
Pr:F:HindIII CCCAAGCTTGAAGATCGACATCATCGACTACGAC
Pr:R:XbaI TGCTCTAGAGATACATGTCCGCACCGGTCCGACAG
2628us:F:XbaI TGCTCTAGAGAACCGCTCATCACACTGTCGCGCAC
2628:R:NheI CTAGCTAGCCACTACTTCTCCTCATCTTGAGGCGAC
2629US:F:XbaI TGCTCTAGAGACACGATGTTCGTCGACATCTC
2629:R:NheI CTAGCTAGCCATCAGGTACGTGCCTTCTCGAC
2630US:F:XbaI TGCTCTAGAGTATCCAGGTCGACGACGAG
2630:R:NheI CTAGCTAGCCATCCTCAGCGTTCGTCC
2631US:F:XbaI TGCTCTAGAGATGCCGGTGACGACAACCGATC
2631:R1:NheI CTAGCTAGCCAAGGGCCCGTGCGAGCGCCTGTAC
a Additional nucleotides not specific for M. smegmatis sequences are shown in bold;
restriction sites are underlined.
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microplate reader, using excitation and emission wavelengths of 395 nm
and 508 nm, respectively.
RESULTS
Bioinformatic analysis of the Mycobacterium MATE family
transporter gene. Comparison of mycobacterial genes predicted
to encode transport proteins revealed a single annotated MATE
efflux pump ORF in all sequenced species except Mycobacterium
leprae: Rv2836c and MSMEG_2631 in M. tuberculosis H37Rv and
M. smegmatis mc2 155, respectively. Both possess 12 likely trans-
membrane domains. MATE family members are divided into
three clusters (NorM and DinF for prokaryotes and a Eukaryote
cluster) (18). Comparison of NorM and DinF homologs to myco-
bacterial MATE proteins using multiple sequence alignment and a
phylogenetic tree (Fig. 1) revealed that mycobacterial MATE pro-
teins clustered with DinF proteins and made a clade withRalstonia
solanacearum DinF, Escherichia coli DinF, and Vibrio cholerae
VcmD. Analysis of putative transmembrane regions 5 and 6 pre-
sented a slightly different picture. Mycobacterial MATEs possess a
GWLGXP motif in place of GKFGXP, which is conserved only in
NorMs, and also possess SALLCPLLV and GSAVAN (conserved
and similar amino acids are in bold and underlined, respectively)
in place of NIXLDYXFI and GAXIAT motifs in DinF (alignments
not shown). Altogether, these analyses suggest that MSMEG_2631
and Rv2836c genes encode highly similar, orthologous, MATE pro-
teins showing overall higher similarity with known DinFs and pos-
sessing similar but less conserved motifs for both NorM and DinF
groups. We propose that MSMEG_2631 gene be named mmp, for
mycobacterial MATE protein, and refer to it by that name below.
Phenotypic characterization of MATE mutants. To examine
the role of the MATE protein in intrinsic drug resistance of M.
smegmatis, an mmp deletion mutant was generated in two steps:
(i) an mmp::Km disruption mutant (LD1158) was created by ho-
mologous recombination, and (ii) the Kmr marker was removed
using the FLP/FRT system to generate the mmp mutant
(LD1184). The disruption mutant (LD1158), in which 1,182 bp of
mmp (1,368 bp) had been replaced by a Km cassette (1,477 bp),
and the unmarked deletion mutant (LD1184), which has only 250
bp of mmp, were confirmed by PCR. To rule out antibiotic cross-
reactivity due to Km resistance, only the unmarked deletion mu-
tant (LD1184) was used to characterize its phenotype.
To identify possible M. smegmatis MATE efflux substrates, we
used Phenotype MicroArray technology, since it facilitates pheno-
type analysis by testing several phenotypes and includes antibiot-
ics, disinfectants, and other toxic compounds, on 10 PM plates
with 	200 different chemicals. PM tests were performed in 96-
well plates containing nutrients and different inhibitors, and in
which a redox indicator measures cell respiration. Potential inhib-
itors were provided in four concentrations, increasing from left to
right on the plate; if inhibition occurs, dye development is less
intense over time. Due to the lack of a standard PM protocol for
M. smegmatiswith inhibitory plates (PM-11 to -20), we attempted
to optimize conditions, including cell density and inoculation
FIG 1 Phylogenetic tree based on neighbor-joining analysis of amino acid sequences of MATE transporters from M. tuberculosis H37Rv (Rv), M. bovis BCG
(BCG), M. smegmatis (MSMEG) and studied homologs from other bacteria (Acinetobacter baumannii [Aba]; Bacteroides thetaiotaomicron [Bth]; Brucella
melitensis [Bme]; Clostridium difficile [Cdi]; Erwinia amylovora [Eam]; Escherichia coli [Eco]; Haemophilus influenzae [Hin]; Neisseria gonorrhoeae [Ngo];
Pseudomonas aeruginosa [Pae]; Ralstonia solanacearum [Rso]; Salmonella enterica [Sen]; Staphylococcus aureus [Sau]; Vibrio cholerae [Vch]; Vibrio parahaemo-
lyticus [Vpa]). Numbers show the bootstrap value for the particular branch.
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fluid modifications, to provide reproducible susceptibility pheno-
types. We tested PM-11 to -20 data reproducibility with replicates
for wild-type cells with IF-10b or 7H9 plus 5% OADC and differ-
ent cell suspension dilutions. Data with 60 dilution of 85% T cell
suspension in IF-10b were fairly reproducible (data not shown).
Data with 7H9 plus 5% OADC were also reproducible, but growth
was slower than preferred.
M. smegmatis has more than 100 putative drug efflux genes
belonging to different families. If some have overlapping substrate
specificity, this may mask the effect of deleting one gene, resulting
in little or no susceptibility difference. With this in mind, we cre-
ated two other unmarked deletion mutants, MSMEG_2619
(efpA) (LD1189) and MSMEG_3563 (LD1192), lacking genes
for reported drug efflux pumps (4), as positive controls to exam-
ine with PM plates. PM data suggested susceptibility differences
for each of the three mutants in comparison to the wild type.
Although differences were small in the majority of wells, suggest-
ing enhanced mutant sensitivity, they were consistent. Drugs and
chemicals identified as likely substrates by PM data for LD1189
and LD1192 include most chemicals reported earlier (4) (data not
shown), which indicates PM reliability for drug susceptibility test-
ing in M. smegmatis.
FIG 2 Phenotype MicroArray PM-11 and PM-12 data comparing the MSMEG_2631 mutant (LD1184) (yellow) with its isogenic parent (blue). Enclosed boxes
indicate the wells in which differences in susceptibility were significant and consistently reproducible. (Upper panel) PM-11 has amikacin, bleomycin, capreo-
mycin, and kanamycin in wells A1 to A4, C1 to C4, D1 to D4, and H5 to H8, respectively. (Lower panel) PM-12 has sulfamethazine, sulfadiazine, sulfathiazole,
and sulfamethoxazole in wells D5 to D8, E5 to E8, F5 to F8, and G5 to G8, respectively. Antibiotic concentration in the four wells increases from left to right. Color
intensity (a measure of cell metabolism) is plotted on the vertical axis versus time on the horizontal axis (168 h in this case).
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PM data for the wild type and LD1184 (Fig. 2) revealed that this
mutant was more susceptible to several antibiotics and antiseptics,
including capreomycin, amikacin, kanamycin, phleomycin, bleo-
mycin, cetylpyridinium chloride, and all sulfa drugs on PM plates
(sulfamethazine, sulfadiazine, sulfathiazole, sulfamethoxazole,
sulfachloropyridazine, and sulfamonomethoxine). PM data re-
vealed that (i) except for sulfa drugs, LD1189 was more suscep-
tible to all compounds listed for LD1184 than LD1184 but not
vice versa, and (ii) LD1184 and LD1192 were equally sensitive
to the sulfa drugs. This observation indicated overlapping gene
functions and prompted us to delete efpA or MSMEG_3563 in
LD1184 to make double mutants LD1190 (MSMEG_2631 and
MSMEG_2619) and LD1201 (MSMEG_2631 and MSMEG_
3563), respectively, to examine the effect of mmp deletion in the
presence and absence of efpA or MSMEG_3563. In most cases,
mmp deletion resulted in a slight decrease in MIC values; however,
double mutants showed greater MIC decreases (Table 3). MICs
for LD1190 (lacking efpA and mmp) were always lower than those
of LD1189 (lacking only efpA), indicating contributions by mmp.
Additionally, in some cases (e.g., capreomycin) a significant MIC
difference for the wild type and for LD1184 was not observed, but
deletion of this gene in the efpA-lacking strain (LD1189) resulted
in further MIC decrease. Similarly, deletion of either mmp or
MSMEG_3563 did not produce a significant difference in some
cases, but deletion of both genes resulted in a greater MIC decrease
in LD1201.
Finally, ethidium bromide and norfloxacin were selected for
susceptibility testing because both are NorM substrates and EtBr is
a preferred DinF substrate (19). Deletion of mmp (mutant
LD1184) rendered the strain more susceptible to EtBr (2-fold de-
crease in MIC) and slightly susceptible for norfloxacin (Table 2),
suggesting that EtBr is a good M. smegmatis MATE substrate and
that this protein provides low-level intrinsic resistance for struc-
turally unrelated compounds.
Effect of mmp and BCG_2856c expression. Data indicating
mmp involvement in multidrug resistance prompted us to exam-
ine complementation and the effect of its expression at higher
levels. We made expression constructs with intermediate (pTB21)
and strong (pUV15) promoters to expressmmp andM. bovisBCG
dinF (BCG_2856c, identical to Rv2836c). Using pUV15 resulted
in growth-defective transformants, with small colonies after a
week. Using pTB21 gave normal transformants, but the expres-
sion constructs grew slowly, and wild-type strains bearing either
pLD216 (pTB21carrying mmp) or pLD217 (pTB21/BCG carrying
dinF) were slightly more sensitive to EtBr and other drugs than
strains bearing empty vector (pTB21). Complemented mutants
bearing expression constructs grew slowly or were slightly more
sensitive to drugs than mutants harboring empty vector. This sug-
gests that higher expression of this gene renders cells growth de-
fective, causing increased sensitivity.
Effect ofmmp deletion on ethidium bromide accumulation
and efflux. Several MATE members are active efflux pumps, the
majority of which (NorM [38], VmrA [39], VcmA [40], VcrM
[41], YdhE [36], and HmrM [42]) are Na dependent. However,
Pseudomonas aeruginosa PmpM (43) and Acinetobacter bauman-
nii AbeM (44) are H coupled. Thus, we examined whether mmp
encoded an active efflux pump and if so, whether it is coupled to
Na or H. We performed EtBr accumulation and efflux assays
with the wild type and LD1184 in the presence and absence of
Na, with the anticipation that (i) mmp deletion would affect
accumulation (positively) and efflux (negatively) if this gene en-
coded an efflux pump and (ii) if mmp encoded an Na-coupled
MATE efflux pump, the effect of mmp deletion would be signifi-
cant in the presence of Na because other EtBr efflux pumps such
as LfrA and EfpA belonging to MFS (both are H coupled) would
not contribute significantly without an energy source. Figure 3A
shows that wild-type cells accumulate 22%, 26%, and 34% less
EtBr in the presence of NaCl, glycerol, or NaCl plus glycerol, re-
spectively, than control cells (with no NaCl or glycerol). With
LD1184, glycerol reduced EtBr accumulation at a rate similar
(28%) to that of the wild type (Fig. 3B). However, NaCl did not
significantly affect EtBr accumulation by LD1184. EtBr efflux data
from preloaded cells (Fig. 3C and D) revealed that EtBr efflux
from wild-type cells was accelerated by either NaCl or glycerol but
in the case of LD1184 only glycerol, and not NaCl, accelerated
efflux. Additionally, efflux was maximum in the presence of NaCl
plus glycerol, but only from wild-type cells. These results support
the hypothesis that the M. smegmatis MATE efflux protein is Na
coupled and active.
mmp organization and its transcriptional linkage with up-
stream genes. To investigate mmp inducibility by EtBr and anti-
biotics with promoter:reporter assays, we analyzed the 600 bp up-
stream to identify a putative mycobacterial promoter consensus
sequence but found none. Further analysis revealed that mmp and
three other upstream ORFs, i.e., MSMEG_2630 (encoding a DHH
family protein), MSMEG_2629 (rbfA, encoding ribosome binding
factor A), and MSMEG_2628 (infB, encoding translation initia-
tion factor IF-2), were present in the same orientation.
MSMEG_2629 and 2630 have an intergenic distance of 2 nucleo-
tides, while MSMEG_2628 and 2629 and MSMEG_2630 andmmp
overlap by 1 and 8 nucleotides, respectively. Since short intergenic
distance and phylogenetically conserved gene order are important
predictors of operon structure for genes in the same orientation
(45), we compared the mmp region with that of other genomes.
This gene order was fairly well conserved in more than 13 actino-
bacteria. Figure 4 shows that gene organization upstream of the
mycobacterial MATE gene is highly conserved, but downstream
TABLE 3 Antimicrobial susceptibility of M. smegmatis mc2 155
mutantsa
M.
smegmatis
strain Description
MIC (g ml1)
EtBr NOR CP KM PM CPC SCP SML SMT
mc2 155 Wild type 4 6 8 4 0.5 10 600 700 600
LD1184 2631 (MATE) 2 5 6 2 0.3 8 400 450 400
LD1189 2619 (efpA) 2 4 5 4 0.3 7 600 700 600
LD1190 2631-2619 1.5 2 3 2 0.15 4 400 500 400
LD1192 3563 3 6 8 2 0.5 10 450 400 450
LD1201 2631-3563 2 4 6 1 0.3 7 300 300 300
a MICs were determined by growth in 8 ml 7H9 –10% OADC– 0.05% Tween 80
supplemented with different concentrations of either EtBr (ethidium bromide), NOR
(norfloxacin), CP (capreomycin), PM (phleomycin), CPC (cetylpyridinium chloride),
SCP (sulfachloropyridazine), SML (sulfamethoxazole), or SMT (sulfamethazine).
Growth was monitored by visual inspection after 3 to 4 days. Experiments were
repeated at least five times to confirm the difference between wild-type and mutant
strains for their susceptibility to these antimicrobial agents. Final concentration ranges
(g/ml): EtBr, 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.5, 5.0, 5.5, 6.0. 6.5, 7.0, 7.5, 8.0; NOR,
1, 2, 3, 4, 5, 6, 7, 8, 9, 10; CP, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10; KM, 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0,
3.5, 4.5, 5.0, 5.5, 6.0; PM, 0, 0.05, 0.1, 0.15, 0.2, 0.25, 0.30, 0.35, 0.45, 0.5, 0.55, 0.6, 0.65,
0.7, 0.75, 0.8; CPC, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20; all sulfa drugs (SCP, SML, and
SMT), 0, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 650, 700, 750, 800, 850, 900,
950, 1,000.
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genes lack a conserved order. ORFs further upstream and in the
same orientation have comparatively long intergenic distances.
Thus, conserved synteny upstream and short intergenic distances
suggest that these four adjacent codirectional genes constitute an
operon and that possible functional or regulatory relationships
exist among these apparently unrelated genes.
This analysis also provided insights into discrepancies about
coordinates of the MSMEG_2628 locus (infB) in genome data-
bases (NCBI and JCVI-CMR). Genome region comparison re-
vealed the following: (i) while the size of infB in most actinobac-
teria varies from 2,703 to 3,015 bp, the predicted coordinates
(2708747 to 2710579) for this gene inM. smegmatis (MSMEG_2628)
represent 1,833 bp in both databases; (ii) although in the JCVI-
CMR database the size for MSMEG_2628 is given as 2,805 bp, the
coordinates (2708747 to 2710579) still represent 1,833 bp; (iii) in
the NCBI genome database, ORF length (1,833 bp) is given ac-
cording to the above coordinates; and (iv) an additional ORF
(MSMEG_2627) has been annotated between MSMEG_2626 and
MSMEG_2628 in the opposite transcriptional direction. On the
basis of these analyses, we extended MSMEG_2628 according to
the given ORF size (2,805 bp) and protein size (934 amino acids)
in the JCVI-CMR database, which resulted in new coordinates
(2707775 to 2710579). Additionally, we propose to remove
MSMEG_2627 (not shown in figures) from the M. smegmatis ge-
nome because annotation of MSMEG_2627 is probably the
consequence of a long intergenic gap between MSMEG_2626
and MSMEG_2628 due to erroneous short coordinates for
MSMEG_2628; an MSMEG_2627 homolog was not found in any
bacteria.
To examine the above prediction regarding transcriptional
linkage among MSMEG_2628-2629-2630-2631, we performed
one-step RT-PCR using total RNA as the template with four dif-
ferent primer sets to amplify fragments encompassing portions of
MSMEG_2628 and 2629 (843 bp), MSMEG_2629 and 2630 (857
bp), MSMEG_2630 and mmp (878 bp), and mmp (462 bp, as
internal control), covering overlapping regions. All produced
fragments of expected sizes (Fig. 5A), supporting the hypothesis
that these four genes are present on the same transcript. To
confirm the presence of one transcript for MSMEG_2628-2629-
2630-2631 and rule out possible amplification from different
overlapping transcripts, we used an mmp-specific reverse primer
(2631-SP1:R) for reverse transcription of RNA into cDNA, which
was used as the template in different PCRs with above primer sets.
Amplification of properly sized fragments (data not shown) con-
firmed the operonic organization of MSMEG_2628-2629-2630-
2631.
Transcription start site identification. Although demonstra-
tion of an MSMEG_2628-2629-2630-2631 operon suggested that
FIG3 Effect of deletion of MSMEG_2631 gene on accumulation (A and B) and efflux (C and D) of ethidium bromide (EtBr) in the presence and absence of NaCl.
Effect of 0.2% glycerol and/or 50 mM NaCl on accumulation of EtBr by the wild type (A) and LD1184 (B). Effect of 0.2% glycerol and/or 50 mM NaCl on efflux
of EtBr from preloaded wild type (C) and LD1184 (D).
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its transcription start site (TSS) and promoter is upstream of
MSMEG_2628, it did not rule out a separate promoter for only
mmp, upstream in MSMEG_2630. To identify themmppromoter,
the TSS was determined by 5=RACE using RNA from M. smegma-
tis treated with EtBr (to find an EtBr-inducible promoter, if pres-
ent). Analysis of products from the second nested PCR in which
anchor/2628-SP2:R or anchor/2631-SP3:R primer sets were used
to amplify upstream regions of MSMEG_2628 or mmp, respec-
tively, revealed a fragment produced with the former primer set,
while amplification was not observed the with latter primer set.
Length (	5 kb) may be a reason for lack of amplification in the
case of anchor/2631-SP3:R with the same cDNA, because these
primers bind to two cDNA ends (Fig. 5C) reverse transcribed from
MSMEG_2628-2629-2630-2631 mRNA. Amplification with an-
chor/2628-SP2:R primer sets, but not anchor/2631-SP3:R with
the same cDNA, indicated that TSSs and the promoter for this
operon might be upstream of MSMEG_2628.
5=RACE revealed a single TSS from a G residue, in the third
base of the annotated predicted start codon (GTG) of MSMEG_2626
ORF and located at position 451 bp relative to the newly pre-
dicted translational start site of MSMEG_2628 (Fig. 5B and C).
Analysis of the region upstream of the identified TSS for promoter
elements revealed sequences of TTCAAA at 35 and TAGACT
at10 of TSS with 18-nt spacing (Fig. 5C). Surprisingly, the presence
of the TSS after the MSMEG_2626 start codon suggested that (i)
MSMEG_2626 is translated from a start codon located down-
stream of the determined TSS and (ii) MSMEG_2626 is part of the
same operon (MSMEG_2628-2627-2630-2631) predicted above
to be comprised of only 4 ORFs. Initially, due to a 102-bp inter-
genic space between MSMEG_2626 and MSMEG_2628, we did
not predict MSMEG_2626 to be in this operon, but TSS determi-
nation revealed that the operon is comprised of 5 ORFs
(MSMEG_2626-2628-2629-2630-2631), starting from MSMEG_
2626 and ending with mmp.
To identify a translational start site for MSMEG_2626, we
compared its genomic organization, size, and sequences with
those of homologs, revealing that (i) an MSMEG_2626 homolog is
present in all sequenced actinobacteria; (ii) it is usually annotated
as a conserved hypothetical protein, but in Corynebacterium spe-
cies it is implicated in transcription termination; (iii) it showed
conserved synteny (located upstream of infB, encoding transla-
tion initiation factor IF-2); (iv) although the M. tuberculosis
H37Rv and M. bovisBCG nucleotide sequences were identical, the
predicted ORF sizes in these species were 360 bp and 300 bp,
respectively; (v) the annotated size of MSMEG_2626 ORF was 351
bp (starting 2 bp upstream of the TSS). A search downstream of
the determined TSS in M. smegmatis revealed potential start
codons 61 bp (GTG) or 94 bp (TTG) downstream of the TSS,
making 288- or 255-bp ORFs, respectively. On the basis of this
analysis, we cannot assign a start codon with certainty, but we
speculate that it is GTG because the 288-bp size is close to that of
BCG (300 bp).
Confirmation of promoter activity. We then investigated ac-
tivity and inducibility of the identified single MSMEG_2626-
2628-2629-2630-2631 promoter and whether the upstream re-
gions of MSMEG_2629, _2630, or mmp had promoter activity. To
examine activity and inducibility, a 375-bp fragment encompass-
ing bp 325 to 50 from the TSS was inserted upstream of a
promoterless lacZ reporter in pLD150 to construct a promoter:
lacZ transcriptional reporter fusion (pLD226), and promoter ac-
tivity and inducibility was monitored by measuring -galactosi-
dase activity of M. smegmatis cells harboring pLD150 or pLD226,
grown in the absence or presence of different drugs. Figure 6A
shows that significant activity was observed in the cells harboring
pLD226. Activity was not affected by any tested drugs likely to be
efflux pump substrates (data not shown). These results validate
the TSS determination and indicate constitutive regulation of the
MSMEG_2626-2628-2629-2630-2631 operon.
To examine whether other ORFs of this operon have promoter
activity in their upstream regions, promoter:gfpuv translational
fusions were constructed by replacing the pTB21 promoter with
approximately 1,000-bp upstream regions (including the start
codon) of MSMEG_2628 (pLD222), MSMEG_2629 (pLD223),
MSMEG_2630 (pLD224), or mmp (pLD225). Promoter activity
FIG 4 Genomic organization of the gene encoding the MATE family protein in Mycobacterium smegmatis mc2 155 (A), M. tuberculosis H37Rv (B), and
Corynebacterium glutamicum ATCC 13032 (C). Horizontal arrows represent the relative positions and orientations of annotated ORFs predicted to encode
hypothetical (hatched) or known (gray, black, or white) proteins. Numbers with vertical thin and thick arrows indicate the intergenic and shared nucleotides,
respectively. Black, light gray, and dark gray arrows indicate ORFs predicted for multidrug and toxic compound extrusion (MATE) family protein, ribosomal
binding factor (rbfA), and translation initiation factor (infB), respectively. White arrows indicate the ORFs predicted to encode different proteins in these
bacteria: MSMEG_2625/Rv2841c/Cg2178 (transcription elongation factor, NusA); MSMEG_2632 (SAM-dependent methyltransferase); MSMEG_2633 (ABC
transporter ATP-binding protein); Rv2835c-Rv2834c-Rv2833c (components of an ABC transporter encoded by ugpAEB, respectively); Cg2177 (nucleic acid
binding protein implicated in transcription termination); Cg2174 (exopolyphosphatase); Cg2172 (serine/threonine-specific protein phosphatase); Cg2171
(phosphopantetheinyl transferase); Cg2170 (tRNA pseudouridine synthase).
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was monitored by measuring fluorescence of cells harboring these
plasmids, pLD221 (negative control), or pTB21 (positive control).
From the data shown in Fig. 6B, it is obvious that only pLD222 or
pTB21 expresses gfpuv, indicating that the sole promoter is located
upstream of MSMEG_2628 and that MSMEG_2629, _2630, and
mmp do not have a promoter in their upstream region. Quantifi-
cation of GFPuv fluorescence indicated that this operon is regu-
lated by a somewhat stronger promoter than the mycobacterial
intermediate promoter in pTB21. High-level GFPuv expression
by pLD222, which has the upstream region of MSMEG_2628
(1,011-bp fragment including the determined TSS and promot-
ers) with its start codon GTG, strengthens our proposal of new
MSMEG_2628 coordinates and validates the TSS and promoter
for this operon.
DISCUSSION
Initially, intrinsic drug resistance was characterized as a passive
mechanism associated with the absence of the drug target or lack
of bacterial permeability (15, 16), but recent studies have estab-
lished that it can depend on drug efflux (46–48). Efflux pumps can
contribute to acquired drug resistance due to overexpression (24,
49) and to MDR (24, 50, 51). Drug efflux families, the MATE
family being the most recently added group (18), have been stud-
ied for function and physiological importance (52).
For Mycobacterium intrinsic drug resistance, strong support
exists for a major role for low cell wall permeability (15, 16) and an
array of efficient multidrug efflux pumps (17). LfrA, an MFS efflux
pump that confers resistance to fluoroquinolones, EtBr, acridine,
and quaternary ammonium compounds, was the first such pump
characterized in mycobacteria (53). More recently, other efflux
pumps have been demonstrated to be involved in mycobacterial
drug resistance (17). Several approaches were used in these stud-
ies: (i) monitoring drug resistance change due to efflux gene ex-
pression in a suitable host, which suggests involvement in efflux
but which does not demonstrate an endogenous role or physio-
logical importance; (ii) genome-wide expression analysis in re-
sponse to drugs, which can identify inducible efflux genes and
provide insights into their importance during drug exposure but
which cannot identify constitutively expressed genes; (iii) moni-
toring drug resistance changes due to efflux gene deletion, which is
a straightforward strategy but works only if the genes of interest
encode a dominant efflux protein and other genes do not encode
proteins with similar specificity (which may mask the effect of
deletion).
FIG 5 Demonstration of transcriptional linkage between MSMEG_2626-2628-2629-2630-2631 and determination of transcription start site (TSS) for this
operon by 5=RACE. (A) Agarose gel showing reverse transcriptase PCR-amplified products obtained (numbers in parentheses refer to regions used to design
primers, shown in panel C): 2628:F (1)/2629:R (2) (lane 2, 843 bp), 2629:F (3)/2630:R (4) (lane 3, 857 bp), 2630:F (5)/2631:R (6) (lane 4, 878 bp), and 2631:F
(7)/2631:R (6) (lane 5, 462 bp) from RNA isolated fromMycobacterium smegmatismc2 155. Lane 1 shows the bands of 1-kb DNA ladder (GeneRuler; Fermentas).
(B) Electropherogram showing TSS (enclosed in box) is representative of results from sequencing of several distinct clones obtained after 5=RACE experiment.
(C) Schematic representation of MSMEG_2628-2629-2630-2631 chromosomal region of M. smegmatis. Large and filled arrows represent the relative size,
location, and transcriptional orientation of ORFs. Small and thin arrows represent the regions used to design primers for reverse transcriptase PCR (designated
by numbers) and 5=RACE experiment (designated by letters); 2631-SP1:R (a), 2631:SP2:R (b), 2631-SP3:R (c), 2628-SP1:R (d), and 2628-SP2:R (e). Nucleotides,
from509 to 10 bp of the translational start site (bold and underlined) according to the new coordinates of MSMEG_2628, show TSS (nucleotide written in
blue and indicated as1),35 and10 regions (bold and overlined sequences), and a possible ribosomal binding site (bold and italicized). Start or stop codons
for MSMEG_2626, according to genome databases, are indicated by underlined or bold nucleotides, respectively. Proposed start codons for MSMEG_2626 are
indicated by italicized and overlined sequences.
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M. smegmatis has more than 100 predicted drug efflux pump
genes from all drug efflux families, but this number is 3 times
lower in M. tuberculosis, which might arise from niche differences
or reduction in genome size. The large number of efflux pumps in
M. smegmatis makes this bacterium a more complicated system
due to overlapping specificities. Our analysis revealed a single an-
notated MATE family efflux gene in all Mycobacterium species
except M. leprae, which suggested that although not essential, this
protein is important for mycobacterial physiology.
Several MATE homologs confer resistance to fluoroquinolo-
nes (norfloxacin), cationic dyes (acriflavine and ethidium), and
aminoglycosides (e.g., kanamycin and streptomycin) (19). Our
data indicate that mmp deletion results in slightly increased sus-
ceptibility for several drugs, but its deletion in mutants lacking
MSMEG_2619 (efpA) or MSMEG_3563 decreased MIC values
further, supporting the importance of M. smegmatis MATE. This
also suggested that in some cases deletion of only mmp might not
result in observable MIC differences because its loss can be
masked by other pumps with overlapping substrate specificity. Of
importance, the use of the Biolog PM in this study helped us ex-
plore the polyspecific nature of M. smegmatis MATE efflux by
identifying capreomycin, phleomycin, sulfa drugs, and cetylpyri-
dinium chloride as new substrates.
Expression of mmp or BCG2856 (dinF) with an intermediate
promoter (pTB21) rendered the cells slow growing and slightly
more drug sensitive, which was emphasized during expression
with a strong promoter (pUV15); both phenotypes likely result
from excessive gene expression. Such deleterious effects have been
associated with membrane disruption or undesirable metabolite
export (54, 55).
All studied MATE efflux pumps, except P. aeruginosa PmpM
and A. baumannii AbeM, are Na coupled (19). Our EtBr accu-
mulation and efflux data support an Na-dependent nature for
M. smegmatis MATE efflux. Although the effect of mmp deletion
on drug susceptibility was somewhat masked by MSMEG_2619
(efpA) and MSMEG_3563, this deletion significantly affected EtBr
accumulation and efflux because of its Na dependence, which
enabled it to function in starved cells in the presence of NaCl,
while ABC, MFS, RND, and SMR efflux pumps could not work.
The genomic organization of MATE efflux pump gene flanking
regions has been studied in DinFs in several bacteria (24, 56–58).
In E. coli and Streptococcus pneumoniae, dinF is in operons with
lexA and recA, respectively (56, 57). In Staphylococcus aureus, the
mepRAB operon encodes a MarR-like transcriptional regulator
(mepR), a MATE family efflux pump (mepA), and a hypothetical
protein (mepB) (24). InRalstonia solanacearum, dinF is flanked by
genes encoding a hypothetical amino acid permease and a putative
transmembrane protein (58). These studies demonstrate that bac-
terial dinF-flanking regions lack conserved synteny. Our study of
the mmp region revealed an MSMEG_2626-2628-2629-2630-
FIG 6 Estimation of promoter activity using promoter:lacZ transcriptional (A) and promoter:gfpuv translational (B) fusions. (A) -Galactosidase activity of
pLD150 (empty vector) and pLD226 (construct having a 375-bp fragment encompassing nucleotides325 to50 of determined TSS). (B). Expression of gfpuv
from translational fusions constructed with upstream regions of MSMEG_2628 (pLD222), MSMEG_2629 (pLD223), MSMEG_2630 (pLD224), and MS-
MEG_2631 (pLD225). (I) 7H10 plate showing the expression of gfpuv in M. smegmatis harboring pTB21 (1) (positive control), pLD221 (2) (negative control,
lacking the pTB21 promoter), pLD222 (3), pLD223 (4), pLD224 (5), or pLD225 (6). (II) Quantification and comparison of fluorescence intensity levels in M.
smegmatis cells harboring translational fusions.
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2631 operon, conserved synteny of the upstream region, and a
downstream region lacking conserved gene order. AlthoughE. coli
(lexA-dinF) and S. aureusmepRAB present only two MATE exam-
ples, drug efflux genes in an operon with a transcriptional regula-
tor are common in MFS. The E. coli lexA-dinF and S. pneumoniae
dinF-recAoperons are examples of transcriptional linkage of genes
involved in DNA damage response. However, the mycobacterial
MATE operon provides an exciting, new example of transcrip-
tional coupling of a MATE efflux gene, with genes encoding pro-
teins with apparently unrelated functions, since infB and rbfA en-
code translation proteins and MSMEG_2630 encodes a DHH
family protein reported in E. coli (59) and Thermus thermophilus
(60) to be involved in DNA base excision-repair and recycling of
short oligonucleotides, respectively. Although association with a
DHH gene can be explained on the basis of involvement of MATE
and DHH in DNA damage response, association with infB and
rbfA, which indicates involvement of MATE protein in other im-
portant cellular physiologies, cannot be explained without further
research.
The norM promoter is induced at 18°C in Erwinia amylovora
(61), DNA-damaging compounds induce dinF in Clostridium dif-
ficile (62) andR. solanacearum (58), andmepRnegatively regulates
S. aureus mepB MATE transcription (24). Our data indicate that
MSMEG_2626-2628-2629-2630-2631 operon transcription is ini-
tiated from a single TSS and suggest that the promoter is consti-
tutive, since no tested drugs induce promoter activity. Addition-
ally, translational fusion data indicate that this promoter is
stronger than the mycobacterial intermediate promoter in pTB21
and that the downstream ORFs in this operon lack promoters in
their upstream regions. Presence of a strong promoter might ex-
plain lack of induction in response to drugs, since further induc-
tion might not be required if it is already well expressed, and lack
of induction suggests that although M. smegmatis maintains a suf-
ficient amount of this gene product, it does not benefit from (and
may suffer from) increased expression.
This study provides evidence that M. smegmatis encodes an
Na-dependent MATE family multidrug efflux pump from mmp,
which contributes to intrinsic resistance against antibiotics, DNA-
damaging chemicals, and disinfectants.mmp is a part of an operon
that includes genes encoding proteins with apparently unrelated
functions and is expressed efficiently from a strong constitutive
promoter. By confirmation of transcriptional linkage, determina-
tion of the TSS, and estimation of promoter activity, we can now
(i) correct the MSMEG_2628 coordinates by replacing positions
2708747 to 2710579 (given in databases) with positions 2707775
to 2710579 (proposed); (ii) remove MSMEG_2627 from the M.
smegmatis genome, because its annotation is probably the conse-
quence of a long intergenic gap associated with short coordinates
for MSMEG_2628 and since a homolog for this protein was not
found in any bacteria; (iii) indicate a new translational start site for
MSMEG_2626, since the predicted start codon is located within
the determined TSS.
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